Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Thanks for listening, PEPFAR, but could you come a little closer? Civil society members answer questions on HIV response planning
Analysis finds gaps, opportunities, and appreciation as the President’s Emergency Plan for AIDS Relief opens door to local advocates, implementers, and affected populations On paper, the […]
To develop tools to meet the goals set out in the World Health Organization End TB strategy, which includes reducing tuberculosis incidence by 80 percent and […]
Survey responses across 12 countries, six regions show range of awareness, common dangers, failures to communicate . . . On the positive side, two-thirds of a […]
On sexual minorities, development, and Uganda and more, Barney Frank notes: “You didn’t tell me to mind my own business when I was pushing for a billion dollars in debt relief . . .”
“One of the little lies that people tell is, ‘Oh, I don’t like to say I told you so,'” former Rep. Barney Frank reflected Wednesday, before […]